LEUKOCARE

16 articles about LEUKOCARE

• 

  German Biotech Receives $17.5M to Expand in U.S.

  6/24/2021

  German biotechnology firm LEUKOCARE, which has operations in Milford, Connecticut, has announced the closing of $17.5 million financing round from New York investment firm Petrichor Healthcare Capital Management. 

• Leukocare Announces USD 17.5 Million Financing Round to Further Expand US Business and Bioinformatics Activities

  6/23/2021

  Leukocare AG, a biotechnology company specialized in the field of biopharmaceutical formulation development, announced the closing of a USD 17.5 million financing, led by Petrichor Healthcare Capital Management, with participation from existing Leukocare shareholders.

• Rentschler Biopharma and Leukocare extend service offering with joint U.S. site

  3/22/2021

  Leukocare joins Rentschler Biopharma in the U.S., facilitating integrated alliance capabilities and enhanced service for North American clients

• Leukocare starts operations in the US and opens development laboratories and offices in Boston Metropolitan Area

  1/11/2021

  Leukocare AG, a German biotechnology company specialized in formulation development for biologics, viral vectors and vaccines, announced the opening of its development laboratories and offices in Milford, MA, USA.

• ReiThera, LEUKOCARE and Univercells announce pan-European consortium for the fast-track development of a single-dose adenovirus-based COVID-19 vaccine

  4/23/2020

  Italian ReiThera Srl., German LEUKOCARE AG, and Belgian Univercells S.A., announced a strategic collaboration for the development and large-scale manufacturing of a novel adenoviral vector-based vaccine against COVID-19.

• Informa 2018 Survey predicts Drug Product Formulation Recognition and Budgets to increase significantly

  11/6/2018

  Formulation issues cause significant drug project delays and project failures, as experienced by 60% of survey participants.

• Rentschler Biopharma and LEUKOCARE to announce findings of recent international Drug Product Formulation Survey at BIO-Europe® 2018

  10/24/2018

  The survey provides latest insights into the status quo and future of drug product formulation and its potential to refine all steps in the biopharmaceutical value chain.

• LEUKOCARE and Xellia Pharmaceuticals partner to discover innovative formulations for the development of value-added anti-infective therapies

  9/10/2018

  LEUKOCARE AG and Xellia Pharmaceuticals, have entered into a global strategic partnership, where both companies will collaborate closely to discover innovative and superior formulations to support the development of Xellia’s pipeline of value-added antibiotic and antifungal products which are intended to enhance patient care.

• Rentschler Biopharma and Leukocare Demonstrate Success of Strategic Alliance for Biopharmaceutical Development and Formulation

  3/9/2018

  Integration of best-in-class formulation in the biopharmaceutical development process adds significant value and improves speed to market

• LEUKOCARE Continues To Expand And Invests In Research And Development

  9/14/2017

• Rentschler Biotechnologie GmbH & Co. And LEUKOCARE Announce Strategic Alliance And Equity Investment

  2/2/2017

• LEUKOCARE Grants License To US Vaccine Company PaxVax, Inc.

  9/13/2016

• Former Sandoz CEO Joins Supervisory Board Of LEUKOCARE

  7/15/2016

• LEUKOCARE Receives Growth Capital Funding And Strengthens Its Board With Industry Experts

  7/22/2015

• LEUKOCARE Licenses Its Stabilizing And Protecting Technologies For Veterinarian Vaccine

  12/4/2013

• Xenios and LEUKOCARE Announce Strategic Partnership in the Field of Anti-Inflammatory Coatings for Next Generation Extracorporeal Support Systems

  10/1/2013